(ELAN) Elanco Animal Health - Overview
Stock: Parasiticides, Vaccines, Therapeutics, Antibiotics, Feed Additives
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 41.9% |
| Relative Tail Risk | -18.7% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 1.65 |
| Alpha | 90.27 |
| Character TTM | |
|---|---|
| Beta | 1.309 |
| Beta Downside | 1.219 |
| Drawdowns 3y | |
|---|---|
| Max DD | 56.10% |
| CAGR/Max DD | 0.45 |
Description: ELAN Elanco Animal Health January 06, 2026
Elanco Animal Health (NYSE: ELAN) develops, manufactures and markets a broad portfolio of animal-health products for pets and livestock, ranging from parasiticides (Seresto, Credelio) and vaccines to therapeutics such as Galliprant for canine osteoarthritis. Its farm-animal line includes medicated feed additives, injectable antibiotics (Baytril), and disease-prevention vaccines for cattle, swine and poultry (e.g., Rumensin, Maxiban).
Key financial metrics from the most recent FY2023 filing show total revenue of approximately $3.6 billion, with pet-care sales contributing roughly 45 % and livestock products the remainder; adjusted EBITDA margin hovered around 12 %, reflecting ongoing cost-discipline but also pressure from higher raw-material costs. The pet-care segment is benefitting from a secular 5-6 % CAGR in U.S. pet spending, while the livestock side faces tighter regulatory scrutiny on antibiotic use, a factor that could reshape product mix in the next 12-24 months.
Assuming the company can sustain its pipeline of next-generation parasiticides and expand its Galliprant indication set, the upside potential is tied to two drivers: (1) continued growth in the premium-pet market, which historically outperforms broader consumer cycles, and (2) the global demand for sustainable livestock production, which may increase adoption of feed-additive solutions despite regulatory headwinds. A downside risk is a possible slowdown in veterinary clinic visits if economic conditions tighten, which would directly depress prescription-drug volumes.
For a deeper dive into ELAN’s valuation sensitivities and comparable peer analysis, you might find the data tools on ValueRay useful.
Piotroski VR‑10 (Strict, 0-10) 3.5
| Net Income: 36.0m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.03 > 0.02 and ΔFCF/TA -0.19 > 1.0 |
| NWC/Revenue: 44.39% < 20% (prev 45.91%; Δ -1.52% < -1%) |
| CFO/TA 0.05 > 3% & CFO 629.0m > Net Income 36.0m |
| Net Debt (3.52b) to EBITDA (891.0m): 3.95 < 3 |
| Current Ratio: 2.40 > 1.5 & < 3 |
| Outstanding Shares: last quarter (496.8m) vs 12m ago -0.18% < -2% |
| Gross Margin: 46.37% > 18% (prev 0.43%; Δ 4595 % > 0.5%) |
| Asset Turnover: 34.22% > 50% (prev 33.53%; Δ 0.69% > 0%) |
| Interest Coverage Ratio: 0.93 > 6 (EBITDA TTM 891.0m / Interest Expense TTM 237.0m) |
Altman Z'' 0.31
| A: 0.15 (Total Current Assets 3.49b - Total Current Liabilities 1.46b) / Total Assets 13.55b |
| B: -0.14 (Retained Earnings -1.91b / Total Assets 13.55b) |
| C: 0.02 (EBIT TTM 221.0m / Avg Total Assets 13.42b) |
| D: -0.31 (Book Value of Equity -2.10b / Total Liabilities 6.80b) |
| Altman-Z'' Score: 0.31 = B |
Beneish M -3.11
| DSRI: 1.05 (Receivables 975.0m/904.0m, Revenue 4.59b/4.45b) |
| GMI: 0.92 (GM 46.37% / 42.68%) |
| AQI: 0.95 (AQ_t 0.64 / AQ_t-1 0.67) |
| SGI: 1.03 (Revenue 4.59b / 4.45b) |
| TATA: -0.04 (NI 36.0m - CFO 629.0m) / TA 13.55b) |
| Beneish M-Score: -3.11 (Cap -4..+1) = AA |
What is the price of ELAN shares?
Over the past week, the price has changed by +4.65%, over one month by +5.88%, over three months by +17.10% and over the past year by +110.53%.
Is ELAN a buy, sell or hold?
- StrongBuy: 6
- Buy: 1
- Hold: 8
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the ELAN price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 25.9 | 2.9% |
| Analysts Target Price | 25.9 | 2.9% |
| ValueRay Target Price | 27.3 | 8.1% |
ELAN Fundamental Data Overview February 07, 2026
P/E Forward = 23.2558
P/S = 2.631
P/B = 1.7963
P/EG = 4.2251
Revenue TTM = 4.59b USD
EBIT TTM = 221.0m USD
EBITDA TTM = 891.0m USD
Long Term Debt = 3.96b USD (from longTermDebt, last quarter)
Short Term Debt = 62.0m USD (from shortTermDebt, last quarter)
Debt = 4.02b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 3.52b USD (from netDebt column, last quarter)
Enterprise Value = 15.60b USD (12.08b + Debt 4.02b - CCE 505.0m)
Interest Coverage Ratio = 0.93 (Ebit TTM 221.0m / Interest Expense TTM 237.0m)
EV/FCF = 43.09x (Enterprise Value 15.60b / FCF TTM 362.0m)
FCF Yield = 2.32% (FCF TTM 362.0m / Enterprise Value 15.60b)
FCF Margin = 7.88% (FCF TTM 362.0m / Revenue TTM 4.59b)
Net Margin = 0.78% (Net Income TTM 36.0m / Revenue TTM 4.59b)
Gross Margin = 46.37% ((Revenue TTM 4.59b - Cost of Revenue TTM 2.46b) / Revenue TTM)
Gross Margin QoQ = 53.39% (prev 46.49%)
Tobins Q-Ratio = 1.15 (Enterprise Value 15.60b / Total Assets 13.55b)
Interest Expense / Debt = 1.29% (Interest Expense 52.0m / Debt 4.02b)
Taxrate = 30.74% (150.0m / 488.0m)
NOPAT = 153.1m (EBIT 221.0m * (1 - 30.74%))
Current Ratio = 2.40 (Total Current Assets 3.49b / Total Current Liabilities 1.46b)
Debt / Equity = 0.60 (Debt 4.02b / totalStockholderEquity, last quarter 6.75b)
Debt / EBITDA = 3.95 (Net Debt 3.52b / EBITDA 891.0m)
Debt / FCF = 9.72 (Net Debt 3.52b / FCF TTM 362.0m)
Total Stockholder Equity = 6.49b (last 4 quarters mean from totalStockholderEquity)
RoA = 0.27% (Net Income 36.0m / Total Assets 13.55b)
RoE = 0.55% (Net Income TTM 36.0m / Total Stockholder Equity 6.49b)
RoCE = 2.11% (EBIT 221.0m / Capital Employed (Equity 6.49b + L.T.Debt 3.96b))
RoIC = 1.43% (NOPAT 153.1m / Invested Capital 10.73b)
WACC = 8.28% (E(12.08b)/V(16.10b) * Re(10.74%) + D(4.02b)/V(16.10b) * Rd(1.29%) * (1-Tc(0.31)))
Discount Rate = 10.74% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 0.41%
[DCF Debug] Terminal Value 73.82% ; FCFF base≈369.2m ; Y1≈305.0m ; Y5≈220.3m
Fair Price DCF = 0.64 (EV 3.84b - Net Debt 3.52b = Equity 316.0m / Shares 496.9m; r=8.28% [WACC]; 5y FCF grow -20.95% → 2.90% )
EPS Correlation: -41.14 | EPS CAGR: -54.69% | SUE: -2.79 | # QB: 0
Revenue Correlation: 8.22 | Revenue CAGR: 0.57% | SUE: 2.58 | # QB: 3
EPS next Quarter (2026-03-31): EPS=0.35 | Chg30d=-0.001 | Revisions Net=+0 | Analysts=10
EPS next Year (2026-12-31): EPS=1.03 | Chg30d=-0.005 | Revisions Net=-1 | Growth EPS=+9.6% | Growth Revenue=+5.7%